Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Health Technology Assessment2011Vol. 15(14), pp. 1–278
Citations Over TimeTop 1% of 2011 papers
K Malottki, Pelham Barton, A Tsourapas, Olalekan A. Uthman, Zhihong Liu, K Routh, Martin Connock, Paresh Jobanputra, David Moore, A Fry-Smith, Yen‐Fu Chen
Abstract
This study was funded by the Health Technology Assessment programme of the National Institute for Health Research.
Related Papers
- → A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis(2018)20 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].(2007)
- → P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)(2020)
- → Biologic Therapy of Ulcerative Colitis: Infliximab, Adlimumab, Golimumab(2011)